{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-obstructive-pulmonary-disease/prescribing-information/antibiotics/","result":{"pageContext":{"chapter":{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics","depth":2,"htmlHeader":"<!-- begin field de3fd49a-50a3-439b-85ac-9ab10c4666c2 --><h2>Antibiotics</h2><!-- end field de3fd49a-50a3-439b-85ac-9ab10c4666c2 -->","summary":"","htmlStringContent":"<!-- begin item 0ab7ad12-cb87-480b-a267-23b4f7e91a7c --><!-- end item 0ab7ad12-cb87-480b-a267-23b4f7e91a7c -->","topic":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f","topicId":"e48489e8-63d1-4a04-bc5b-07e36a76af58","topicName":"Chronic obstructive pulmonary disease","slug":"chronic-obstructive-pulmonary-disease","lastRevised":"Last revised in October 2020","chapters":[{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ccd2981-1bc9-5357-86d2-cbf578b57adb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes"},{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update"}]},{"id":"d28cbe2c-ffc9-58ab-913c-3afa52c28841","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"99f07881-2c1a-5874-8cd2-3f10dcb385fa","slug":"goals","fullItemName":"Goals"},{"id":"85c2e06f-fe1e-532b-8752-0337ca19cfe3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f6fa4f07-a45d-5c3e-8c59-2054ea5ecd38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"defe1786-7b6d-5c90-a7f4-0871262dd84f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6356570-e32f-5480-89d6-026b80bb055d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0433c46f-8e2f-53b3-a392-aca635b35160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29a2fdef-c0c3-5bb6-9c12-21d649ed27bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"715af617-76e1-5846-9262-1616f0003270","slug":"definition","fullItemName":"Definition"},{"id":"6f383baf-ff39-58db-b933-24b4c5feb5f8","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"7fe9ff8f-68ba-5f97-91ab-8d23c907b1cf","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4bcdbaec-2487-5733-812a-7ec514939f8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c7c94e20-91a7-5b3d-b8dd-0d4f8d5c023c","slug":"complications","fullItemName":"Complications"}]},{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD"},{"id":"93fac9cc-fc19-5440-8330-f6f56941ddb6","slug":"diagnosis-acute-exacerbation","fullItemName":"Diagnosis - acute exacerbation"}]},{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"4aafe1b6-b17a-51d8-a8f0-104880ac3722","slug":"stable-copd","fullItemName":"Scenario: Stable COPD"},{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation"},{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD"},{"id":"f1d4be42-b98a-55de-860a-3be931c97c1c","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists"},{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"f45aa048-e0b1-55dc-9f40-68f5af6d3b61","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics"},{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline"},{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics"}]},{"id":"81fd9c2f-91c3-5726-b50a-85fc169646d3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b91263e-7dc1-51aa-9976-bd92619d846e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ac29e092-9d36-550e-99e2-c6b478d21c00","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"737d1a20-607a-560b-8522-2ddb2237249b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bec938e3-108f-5f91-9c9b-2c289bae4e07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dc4c2f7c-85ce-5ba5-a2ef-149ee8a9d54d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51ecdba0-ee93-5792-af12-b38cb8f06b8c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9ad1cd46-bf5b-505f-a6d9-bad7287adccc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a811fac9-de1e-598a-9d9c-5fec9f4f8210","slug":"azithromycin","fullItemName":"Azithromycin","depth":3,"htmlHeader":"<!-- begin field ddf8b3b1-f6dd-4b66-9a54-abaa009d42dd --><h3>Azithromycin</h3><!-- end field ddf8b3b1-f6dd-4b66-9a54-abaa009d42dd -->","summary":"","htmlStringContent":"<!-- begin item 685b9e5e-d8a4-4648-8579-abaa009d42a5 --><!-- begin field 9e26de25-01cf-4689-907e-abaa009d42dd --><h4>Contraindications and cautions</h4><ul><li><strong>Do not prescribe azithromycin in people:</strong><ul><li>With severe hepatic impairment.</li></ul></li><li><strong>Prescribe azithromycin with caution in people:</strong><ul><li>Who may be predisposed to prolongation of the QT interval. For example, people with:<ul><li>Congenital or documented acquired QT prolongation.</li><li>Currently receiving treatment with other active substances known to prolong the QT interval, such as antiarrhythmics of classes IA and III.</li><li>With electrolyte disturbance, particularly in cases of hypokalaemia and hypomagnesaemia.</li><li>With clinically relevant bradycardia, cardiac arrhythmia, or severe cardiac insufficiency, including torsades de pointes.</li></ul></li><li>With mild to moderate hepatic impairment.</li><li>With severe renal impairment.</li><li>With myasthenia gravis — macrolides may aggravate symptoms.</li></ul></li></ul><h4>Adverse effects</h4><ul><li><strong>Gastrointestinal</strong> — diarrhoea, abdominal pain, nausea (very common); vomiting, dyspepsia (common); pancreatitis, pseudomembranous colitis (frequency unknown). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li><li><strong>Nervous system</strong> — headache, dizziness, dysgeusia, paraesthesia (common); convulsions, hyperactivity, syncope, myasthenia gravis (frequency unknown).</li><li><strong>Psychiatric</strong> — nervousness (uncommon); aggression, anxiety (frequency unknown).</li><li><strong>Skin</strong> <strong>and subcutaneous tissue</strong> — rash, pruritus (common); Stevens-Johnson syndrome (uncommon); drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalised exanthematous pustulosis (AGEP) (rare); toxic epidermal necrolysis, erythema multiforme (frequency unknown).</li><li><strong>Other common adverse effects include:</strong> <ul><li>Anorexia.</li><li>Arthralgia.</li><li>Deafness.</li><li>Fatigue.</li><li>Visual impairment.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Acute kidney injury.</li><li>QT interval prolongation.</li></ul></li></ul><h4>Drug interactions</h4><ul><li><strong>Antacids </strong>— plasma concentrations of azithromycin may be reduced. Simultaneous administration should be avoided — azithromycin should be taken at least 2 hours before, or 1 hour after antacids.</li><li><strong>Ciclosporin</strong> — azithromycin may increase cyclosporin levels. </li><li><strong>Cisapride </strong>— macrolides increase levels of cisapride, increasing the risk of arrhythmias (Torsade de pointes). Concurrent use is contraindicated.</li><li><strong>Colchicine</strong> — azithromycin slightly increases the levels of colchicine. Monitor for signs of colchicine toxicity (for example, nausea, vomiting, diarrhoea, myopathy, and pancytopenia).</li><li><strong>Digoxin</strong> — cases of increased digoxin levels have been reported. Monitor for signs of digoxin adverse effects (such as bradycardia). Monitor and reduce the digoxin dose if required.</li><li><strong>Edoxaban </strong>— levels may be increased by azithromycin. Dose adjustment of edoxaban may be required.</li><li><strong>Rifabutin</strong> — azithromycin increases the risk of neutropenia when given with rifabutin. Monitor closely.</li><li><strong>Statins </strong>— there is a possible increased risk of myopathy.<ul><li>Advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Typhoid vaccine </strong>— antibacterials might reduce the immune response. The World Health Organization (WHO) recommends that the antibacterial is stopped from 3 days before to 3 days after receiving live oral typhoid vaccine.</li><li><strong>Warfarin</strong> — concurrent use may increase the international normalized ratio (INR). Consider increasing INR monitoring as this interaction appears to develop over the first 7 days.</li><li><strong>Drugs that prolong the QT interval</strong> (such as amiodarone, sotalol, and hydroxyzine) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended. If concurrent use is unavoidable consider ECG (electrocardiogram) monitoring.<ul><li>Concurrent use with domperidone, hydroxyzine, or mizolastine is contraindicated.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, and short-acting beta-2 agonists) — hypokalaemia is a risk factor for QT prolongation.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Joint Formulary Committee, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Preston, 2020</a>]</p><!-- end field 9e26de25-01cf-4689-907e-abaa009d42dd --><!-- end item 685b9e5e-d8a4-4648-8579-abaa009d42a5 -->","subChapters":[]},{"id":"26e6132c-1555-5f46-b381-cb1f61afefaa","slug":"amoxicillin","fullItemName":"Amoxicillin","depth":3,"htmlHeader":"<!-- begin field fdf1cedc-4dd7-4e78-8f76-1751b364c77d --><h3>Amoxicillin</h3><!-- end field fdf1cedc-4dd7-4e78-8f76-1751b364c77d -->","summary":"","htmlStringContent":"<!-- begin item ac0175ed-ca33-443f-a829-b6d8ee8bd017 --><!-- begin field bd86eb04-7641-457e-bc1c-89d0b8b31c82 --><h4>Contraindications and cautions</h4><ul><li><strong>Do not prescribe amoxicillin to:</strong><ul><li>People with a true penicillin hypersensitivity — gastrointestinal adverse effects alone (such as nausea, vomiting, or diarrhoea) do not constitute an allergy to penicillin.</li></ul></li><li><strong>Prescribe amoxicillin with caution in people with:</strong><ul><li>Hypersensitivity to cephalosporins.</li><li>Chronic kidney disease (CKD) — reduce the dose of amoxicillin.</li></ul></li></ul><h4>Adverse effects</h4><ul><li>Gastrointestinal — nausea and diarrhoea (common), vomiting (uncommon).<ul><li>Very rarely: antibiotic-associated colitis (including pseudomembranous colitis and haemorrhagic colitis).</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.  </li></ul></li><li>Skin — skin rash (common), urticaria and pruritus (uncommon).<ul><li>Very rarely: erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous and exfoliative dermatitis and acute generalised exanthematous pustulosis.</li></ul></li><li>Other rare or very rare adverse effects include:<ul><li>Hepatitis, cholestatic jaundice.</li><li>Hyperkinesia, dizziness, convulsions.</li><li>Interstitial nephritis.</li><li>Leucopenia, thrombocytopenia, haemolytic anaemia.</li><li>Seizure.</li><li>Severe allergic reactions.</li></ul></li></ul><h4>Drug interactions</h4><ul><li>Allopurinol — increased risk of rash when allopurinol is given with amoxicillin.</li><li>Warfarin — INR may be increased. Monitor the international normalized ratio (INR) closely during concomitant use. Dosage adjustments may be necessary.</li><li>Methotrexate — amoxicillin may reduce methotrexate clearance, causing an increased risk of toxicity. Consider measuring platelet and white cell counts twice weekly for 2 weeks initially, and measure methotrexate levels if toxicity is suspected.</li><li>Oral hormonal contraception — additional contraceptive precautions are not required during or after courses of amoxicillin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>. </li><li>For more information on drug interactions with amoxicillin, see the British National Formulary.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018r</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field bd86eb04-7641-457e-bc1c-89d0b8b31c82 --><!-- end item ac0175ed-ca33-443f-a829-b6d8ee8bd017 -->","subChapters":[]},{"id":"14435249-b608-5a50-8dfc-1eda3cc37843","slug":"doxycycline","fullItemName":"Doxycycline","depth":3,"htmlHeader":"<!-- begin field 9457fd89-c978-49a2-b877-a76e0102e137 --><h3>Doxycycline</h3><!-- end field 9457fd89-c978-49a2-b877-a76e0102e137 -->","summary":"","htmlStringContent":"<!-- begin item e29d2d77-4265-428a-8b0e-a76e0102df46 --><!-- begin field f3e0a6db-f10a-487d-b0c5-a76e0102e137 --><h4>Contraindications and cautions</h4><ul><li><strong>Do not prescribe doxycycline to:</strong><ul><li>Pregnant or breastfeeding women.</li></ul></li><li><strong>Prescribe doxycycline with caution in people with:</strong><ul><li>Liver problems.</li><li>Systemic lupus erythematosus.</li><li>Myasthenia gravis.</li><li>Renal impairment.</li><li>Porphyria.</li></ul></li></ul><h4>Adverse effects</h4><ul><li>Blood disorders — haemolytic anaemia, thrombocytopenia, neutropenia, eosinophilia.</li><li>Gastrointestinal — nausea, vomiting, dyspepsia. abdominal discomfort, diarrhoea, tooth discolouration and enamel hypoplasia in children.<ul><li>Rarely: dysphagia, oesophagitis, oesophageal irritation, pseudomembranous colitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li>Hepatic disorders – hepatotoxicity, hepatitis, jaundice, hepatic failure.</li><li>Renal disorders — blood urea increased.</li><li>Skin — photosensitivity, rash.<ul><li>Rarely: toxic epidermal necrolysis, Stevens-Johnson syndrome, angioedema, erythema multiforme, exfoliative dermatitis, drug reaction with eosinophilia and systemic symptoms (DRESS).</li></ul></li><li>Other rare adverse effects include:<ul><li>Anaphylaxis.</li><li>Arthralgia, myalgia.</li><li>Bulging fontanelles in infants.</li><li>Flushing.</li><li>Severe headache and/or visual disturbances — may be an early symptom of benign intracranial hypertension, a rare but serious adverse effect.</li><li>Tinnitus.</li></ul></li></ul><h4>Drug interactions</h4><ul><li><strong>Phenobarbital, carbamazepine, phenytoin, and primidone</strong> — metabolism of doxycycline may be accelerated by these drugs, leading to a reduced plasma concentration.<ul><li>Monitor the therapeutic effect of doxycycline, as a dose adjustment may be necessary.</li></ul></li><li><strong>Rifampicin</strong> — may cause a reduction in doxycycline levels, leading to undertreatment.<ul><li>Monitor the effects of concurrent use, dose adjustment may be necessary.</li></ul></li><li><strong>Antacids (containing aluminium, bismuth, calcium, or magnesium) and other medications containing iron or zinc </strong>— these reduce the absorption of tetracyclines if taken concurrently.<ul><li>Avoid taking antacids and other medications containing iron or zinc, 2 hours before or after taking tetracyclines.</li></ul></li><li><strong>Insulin</strong> — the blood-glucose lowering effect may be increased if taken with doxycycline. Monitor blood-glucose levels.</li><li><strong>Lithium</strong> — levels may be increased by doxycycline. Consider increasing the frequency of lithium monitoring.</li><li><strong>Methotrexate</strong> — levels may be increased by doxycycline.</li><li><strong>Warfarin</strong> — the concurrent use of warfarin with tetracyclines may increase the anticoagulant effect.<ul><li>Consider monitoring the person's international normalized ratio (INR) regularly and within 3 days of starting the tetracycline. Adjust the warfarin dose accordingly.</li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of doxycycline.<ul><li>However, advise women about the importance of correct contraceptive practice if they experience vomiting or diarrhoea.</li><li>For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Retinoids</strong> — there is a possible increased risk of benign intracranial pressure if tetracyclines are used concurrently with retinoids (such as isotretinoin).<ul><li>Avoid the concurrent use of tetracyclines and retinoids.</li></ul></li><li>For more information on drug interactions with doxycycline, see the British National Formulary.</li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2019e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field f3e0a6db-f10a-487d-b0c5-a76e0102e137 --><!-- end item e29d2d77-4265-428a-8b0e-a76e0102df46 -->","subChapters":[]},{"id":"20dde187-33e5-57f0-9107-36ec682f7f4f","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":3,"htmlHeader":"<!-- begin field 7431fa8b-bdd8-4d3c-8729-a76e0102f55f --><h3>Clarithromycin</h3><!-- end field 7431fa8b-bdd8-4d3c-8729-a76e0102f55f -->","summary":"","htmlStringContent":"<!-- begin item 91303b71-c688-4053-ac53-a76e0102f302 --><!-- begin field 386dc5e1-7082-4947-9aa4-a76e0102f55f --><h4>Contraindications and cautions</h4><ul><li><strong>Do not prescribe clarithromycin to people:</strong><ul><li>Taking drugs that prolong the QT interval (for example haloperidol, sotalol, terfenadine, and pimozide) — macrolides can also prolong the QT interval, which is a risk factor for torsades de pointes.</li><li>With a history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes.</li><li>With hypokalaemia — due to the risk of prolongation of the QT interval.</li><li>With severe hepatic impairment if they also have renal impairment.</li><li>With statins (such as simvastatin) — due to the increased risk of myopathy, including rhabdomyolysis<strong>.</strong></li><li>With ergot alkaloids or midazolam.</li></ul></li><li><strong>Prescribe clarithromycin with caution to people with:</strong><ul><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (less than 50 beats per minute) — increased risk of QT prolongation. There is an increased risk of death for people with coronary artery disease.</li><li>Electrolyte disturbances, such as hypomagnesaemia.</li><li>Impaired hepatic function – clarithromycin is principally excreted by the liver.</li><li>Myasthenia gravis — macrolides may aggravate symptoms.</li><li>Severe renal impairment (eGFR less than 30 mL/min) — dose adjustment required. </li></ul></li></ul><h4>Adverse effects</h4><ul><li>Gastrointestinal — diarrhoea, vomiting, dyspepsia, nausea, abdominal pain and pancreatitis.<ul><li>Rarely: pancreatitis, pseudomembranous colitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li>Nervous system — headache, dysgeusia, dizziness, somnolence, tremor.<ul><li>Rarely: convulsions, paraesthesia.</li></ul></li><li>Psychiatric — insomnia, anxiety, nervousness.<ul><li>Rarely or very rarely: psychotic disorders, depression, mania, hallucination.</li></ul></li><li>Skin — rash, hyperhidrosis, pruritus, urticaria.<ul><li>Rarely, or very rarely: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Stevens Johnson syndrome, toxic epidermal necrolysis.</li></ul></li><li>Other adverse effects reported uncommonly, rarely, or very rarely, include:<ul><li>Anaphylaxis.</li><li>Arrhythmias.</li><li>Deafness.</li><li>Hepatic failure, jaundice.</li><li>QT interval prolongation.</li></ul></li></ul><h4>Drug interactions</h4><ul><li>Calcium channel blockers (CCBs) — there is an increased risk of hypotension if CCBs, such as verapamil, amlodipine, and diltiazem are taken concomitantly with clarithromycin, as they are metabolised by CYP3A4. This may also lead to increased levels of clarithromycin.</li><li>Ciclosporin — erythromycin can affect clearance of ciclosporin. If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</li><li>Colchicine — azithromycin slightly increases the levels of colchicine. Monitor for signs of colchicine toxicity (for example, nausea, vomiting, diarrhoea, myopathy, and pancytopenia).</li><li>CYP3A enzyme inducers (rifampicin, carbamazepine, phenobarbital) — these may induce the metabolism of clarithromycin, resulting in sub-therapeutic levels.<ul><li>It may be necessary to monitor the levels of these drugs, as CYP3A is inhibited by clarithromycin leading to higher plasma levels of the inducer.</li></ul></li><li>Digoxin — macrolides increase digoxin levels. The risk of toxicity may be lower with azithromycin than with clarithromycin. Monitor and adjust dose if required.</li><li>Edoxaban — levels may be increased by clarithromycin. Dose adjustment of edoxaban may be required.</li><li>Ergot alkaloids — concomitant administration is contraindicated, due to the risk of acute ergot toxicity.</li><li>Oral hormonal contraception — additional contraceptive precautions are not required during or after courses of clarithromycin.<ul><li>However, women should be advised that if diarrhoea, vomiting or breakthrough bleeding occur there is a possibility of contraceptive failure.</li><li>For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li>Oral hypoglycaemic drugs (sulfonylureas) and insulin — the concomitant use of clarithromycin and oral hypoglycaemic drugs and/or insulin can result in significant hypoglycaemia. Monitor glucose levels.</li><li>Statins (atorvastatin, simvastatin) — these are extensively metabolised by CYP3A4. Concomitant administration with clarithromycin increases the plasma levels and the risk of myopathy.<ul><li>Simvastatin — do not prescribe clarithromycin to a person taking simvastatin. If treatment with clarithromycin cannot be avoided, stop treatment with simvastatin temporarily.</li><li>Atorvastatin — avoid concurrent use with clarithromycin. If concurrent use cannot be avoided, prescribe the lowest dose of atorvastatin.</li></ul></li><li>Warfarin — clarithromycin increases the anticoagulant effect of warfarin. Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li><li>Drugs that prolong the QT interval (such as amiodarone, or sotalol) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is contraindicated.</li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2019f</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field 386dc5e1-7082-4947-9aa4-a76e0102f55f --><!-- end item 91303b71-c688-4053-ac53-a76e0102f302 -->","subChapters":[]},{"id":"49f7d764-31f8-57a8-a093-973d32ef8706","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav","depth":3,"htmlHeader":"<!-- begin field 4a235bcb-b2aa-4ce9-b255-a76e01030c28 --><h3>Co-amoxiclav</h3><!-- end field 4a235bcb-b2aa-4ce9-b255-a76e01030c28 -->","summary":"","htmlStringContent":"<!-- begin item 6cbb4b2b-d65b-4f9e-bab8-a76e01030a1b --><!-- begin field 4e40dd39-2275-4ad9-a8a3-a76e01030c28 --><h4>Contraindications and cautions</h4><ul><li><strong>Do not prescribe co-amoxiclav to people with:</strong><ul><li>A true penicillin hypersensitivity. Gastrointestinal adverse effects alone (such as nausea, vomiting, or diarrhoea) do not constitute an allergy to penicillin. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li><li>History of penicillin or clavulanic acid associated hepatic dysfunction.</li></ul></li><li><strong>Prescribe co-amoxiclav with caution to people with:</strong><ul><li>A hypersensitivity to cephalosporins — there is some evidence of partial cross-allergenicity.</li><li>Hepatic impairment – monitor closely.</li><li>Renal impairment — reduce the dose if the estimated glomerular filtration rate (eGFR) is 30 mL/minute/1.73 m<sup>2</sup> or less.</li><li>Acute lymphocytic leukaemia, chronic lymphocytic leukaemia, cytomegalovirus infection, glandular fever — increased risk of erythematous rashes<strong>.</strong></li></ul></li></ul><h4>Adverse effects</h4><ul><li>Gastrointestinal — nausea and vomiting, vomiting.<ul><li>Very rarely: antibiotic-associated colitis.</li></ul></li><li>Nervous system — headache, dizziness.</li><li>Skin — skin rash, urticaria and pruritus, drug reaction with eosinophilia and systemic symptoms (DRESS).<ul><li>Very rarely: erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous and exfoliative dermatitis and acute generalised exanthematous pustulosis.</li></ul></li><li>Other rare, or very rare adverse effects include:<ul><li>Hepatitis, cholestatic jaundice.</li><li>Hyperactivity, convulsions.</li><li>Hypersensitivity reactions (serious and occasionally fatal). </li><li>Interstitial nephritis.</li><li>Leucopenia, thrombocytopenia, haemolytic anaemia.</li></ul></li></ul><h4>Drug interactions</h4><ul><li>Allopurinol — concomitant use of allopurinol and amoxicillin may increase the incidence of skin rashes.</li><li>Methotrexate — co-amoxiclav may reduce methotrexate clearance, causing an increased risk of toxicity.<ul><li>Monitor methotrexate levels more closely. One recommendation is to carry out twice weekly platelet and white cell counts for 2 weeks initially, with the measurement of methotrexate levels if toxicity is suspected.</li></ul></li><li>Mycophenolate mofetil — reduction in the level of active metabolite may occur when given with co-amoxiclav.</li><li>Oral anticoagulants (warfarin, phenindione) — prolongation of prothrombin time has been reported in people taking penicillins and warfarin concurrently.<ul><li>Monitor the prothrombin time or international normalized ratio (INR) more closely with the addition or withdrawal of a penicillin. Adjustment of the anticoagulant dose may be necessary.</li></ul></li><li>Oral hormonal contraception — additional contraceptive precautions are not required during or after courses of co-amoxiclav.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea.</li><li>For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li>Probenecid — concomitant administration may result in increased levels of amoxicillin, but not clavulanic acid</li><li>For more information on drug interactions with co-amoxiclav, see the British National Formulary.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018s</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field 4e40dd39-2275-4ad9-a8a3-a76e01030c28 --><!-- end item 6cbb4b2b-d65b-4f9e-bab8-a76e01030a1b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}